Mon, Nov 16, 2020 | By Cryoport Team
As we approach the annual flu season, Cryoport continues its efforts to proactively monitor the global resurgence of the COVID-19 virus. Cryoport has doubled its efforts to ensure continuity of...
Tue, Oct 20, 2020 | By Adam Fox, Vice President - Quality Assurance & Regulatory Affairs
Cell and gene therapies may be considered novel by the general public today, but they are on the path to dramatically improve the lives of those with chronic conditions and cancers. While a handful...
Mon, Oct 05, 2020 | By Michael Dybicz, Vice President - Consulting Services
Biopharmaceutical supply chains are among the most complex and costly processes on the planet. CAR T-cell therapies, which can cost hundreds of thousands of dollars to create, can be rendered...
Tue, Sep 01, 2020 | By Tom Heinzen, VP, Corporate Development & Investor Relations, Cryoport
Cryoport made two bold moves in the last couple of weeks to further our ability to support the growing number of clinical trials and the coming wave of global commercially approved therapies in the...
Tue, Aug 11, 2020 | By Sue Blecman, Vice President - Global Strategic Business Development, Cryoport
Cryoport recently marked some significant milestones. We are now supporting four commercial biopharma therapies, and a fifth's commercial submission was recently validated by the European Medicines...
Wed, Jun 24, 2020 | By Phil Wilson, Sr. Vice President, Global Logistics and Supply Chain
The last few months have been unprecedented in world history. The pandemic that is gripping the world has spared no country, culture or corner, and it has highlighted the gaps in many companies’...
Tue, Apr 14, 2020 | By Sue Blecman, Vice President - Global Strategic Business Development, Cryoport
As the world experiences unprecedented times caused by the COVID-19 pandemic, Cryoport has been collaborating closely with our clients to help navigate this dynamic environment and to ensure ...
Thu, Feb 06, 2020 | By Phil Wilson, Sr. Vice President, Global Logistics and Supply Chain
Recently the FDA’s Center for Biologics Evaluation and Research issued its guidance to the regenerative medicine industry on best practices for submitting an IND application to the FDA for gene...
Fri, Dec 06, 2019 | By Cryoport Team
New became the norm at Cryoport this year. The company announced new partnerships, new product lines, and new services seemingly every week. On top of these exciting developments were notable...
Thu, Nov 21, 2019 | By Phil Wilson, Sr. Vice President, Global Logistics and Supply Chain
There is no question that the groundbreaking treatments being developed in Cell & Gene Therapy (CGT) are fundamentally changing the way patient care is managed around the world. As with most...
Mon, Oct 28, 2019 | By Cryoport Team
Precision medicine requires end-to-end traceability: everything from chain of custody, to chain of condition, to chain of identity. But the fragility of regenerative medicine therapies – and the need...
Wed, Oct 09, 2019 | By Jill Robinson, Inside Sales Manager
Early approvals of upcoming cell therapies have moved up manufacturing timelines for many firms in the biotech space. This blaze of approvals has been ignited by positive early clinical trial data,...
Wed, Sep 25, 2019 | By Cryoport Team
The incredible advancements of cell and gene therapies are often surprising to those not intimately familiar with the biopharmaceutical industry. After all, whoever would have imagined that a...
Mon, Sep 16, 2019 | By Nathan Dai, Senior Director, Business Development, Cryoport
The human genome and diseases interact in mysterious ways. Along with external factors, these interactions can affect who gets an illness, how serious it gets, at what rate, how the patient responds...
Mon, Aug 26, 2019 | By Ryan Carpentier, Sr. Director, Business Development, Cryoport
The advances in cell and gene therapy over the last few years have been nothing less than remarkable. The amount of resources being poured into their development is reflected in the large number of...
Wed, Aug 21, 2019 | By Lindsay Belcher, Business Development Director - Northeast, Cryoport
Working for a company that supports cell and gene therapy industry, it’s always exciting to see new treatments finally go to market. Drug companies spend years trying to clear their new medicines...
Wed, Aug 14, 2019 | By Ryan Carpentier, Sr. Director, Business Development, Cryoport
Cryoport was honored to be invited to speak at the CAR-T Summit in Shanghai, which gathered the world’s foremost experts on cell and gene therapy. While all presenters highlighted topics that were...
Mon, Jul 08, 2019 | By Kirk Randall, Senior Director, Business Development, Cryoport
We’re proud to provide global support for the first-ever commercial CART-T therapies, produced by our clients Kite (Gilead) and Novartis, as well as bluebird bio’s recently approved gene therapy....
Tue, Jun 25, 2019 | By Sue Blecman, Vice President - Global Strategic Business Development, Cryoport
“By 2025, we predict that the FDA will be approving 10 to 20 cell and gene therapy products a year based on an assessment of the current pipeline and the clinical success rates of these products.” –
Tue, Jun 11, 2019 | By Cryoport Team
This Monday, June 10 was a momentous day for our company: Members of the Cryoport team led the closing bell ceremony at Nasdaq, located in Times Square in New York City. Cryoport stock (CYRX) reached...
Wed, May 29, 2019 | By Tom Heinzen, VP, Corporate Development & Investor Relations, Cryoport
The regenerative medicine sector has grown significantly in the past few years, and it’s showing no signs of slowing down.
Wed, May 08, 2019 | By Cryoport Team
Cryoport is excited to be a Platinum Sponsor of the 2019 World Advanced Therapies and Regenerative Medicine Congress and Expo in London on May 15-17.
Tue, May 07, 2019 | By Nathan Dai, Senior Director, Business Development, Cryoport
There are mainly two types of cooling mechanisms used in the 2-8°C logistics process for biospecimen or drug substances, and they operate on different physics principles.
Wed, Apr 10, 2019 | By Cryoport Team
Technology often evolves faster than laws and regulations can keep up, and the field of regenerative medicine is evolving in the same way.
Americas • EMEA • APAC
Sales • +1 949.470.2300 | Support • +1 949.470.2305
©2023 Cryoport Systems, LLC. All rights reserved.
A Leap Forward in Standardizing the Regenerative Medicine Supply Chain – What the New ISO 21973 Guidance Means for Cell and Gene Therapy Developers
Cryoport® is a trademark of Cryoport, Inc. and used with permission by Cryoport Systems, LLC
